Medtronic VP sells shares; Thermo Fisher launches scholarship program;

@FierceMedDev: Sign up for our new publication, FierceDiagnostics, launching with its first weekly newsletter this Wednesday. Sign up | Follow @FierceMedDev

@DamianFierce: CROs are dishing out more and more bonuses to quell sky-high turnover rates, according to a study. Report | Follow @DamianFierce

@MarkHFierce: Thermo Fisher is rolling out a major scholarship program for science/math students at elite universities. Smart. Release | Follow @MarkHFierce

@MichaelGFierce: Zimmer lands FDA clearance for 3-D surgical system. Article | Follow @MichaelGFierce

> Medtronic ($MDT) vice president H. James Dallas has unloaded 32,332 shares of stock on the open market. Story

> Thermo Fisher Scientific ($TMO) is launching a major scholarship program for students pursuing degrees in science, technology, engineering and math at 5 major universities around the world, including MIT. Item

> A Theragenics-sponsored survey determined that a large majority of men may think they're getting a PSA test as part of overall lab work, even though guidelines recommend against prostate cancer screening for healthy men. Item

> The Society of Laparoendoscopic Surgeons named a surgical closure device made by Suture Ease in Utah as one of its 2013 Innovations of the Year. Item

> Teleflex ($TFX) plans to promote its anesthesia and pain management devices during the ESRA Congress in Glasgow, U.K., from Sept. 4-7, 2013. Item

Biotech News

@FierceBiotech: Rigel shares slide after another drug flops in PhII asthma study. Story | Follow @FierceBiotech

@JohnCFierce: Two years ago Rigel was celebrating when Pfizer turned over R343. Now enthusiasm likely dimmed as top 2 drugs are under a dark cloud. Story | Follow @JohnCFierce

@EmilyMFierce: High copper levels implicated in #Alzheimer's disease. Story | Follow @EmilyMFierce

> Argos turns to unusual players for $42.5M needed to fund PhIII cancer study. News

> AstraZeneca forges $500M cancer-combo tech buyout for MedImmune. More

> Amgen bags Onyx Pharma in $10.4B buyout deal. Story

Pharma News

@FiercePharma: Japan's budget-minded PM wants to open universal health system to more add-on treatments. Could boost cancer meds. Article | Follow @FiercePharma

@EricPFierce: Australia to track Yervoy patients to see if it's worth the $110K price. More | Follow @EricPFierce

@CarlyHFierce: Ex-Novartis chair Vasella considers his results worth the once-approved $78M payout--will make $5.2M instead. Story | Follow @CarlyHFierce

> Australia to track Yervoy patients to see if it's worth the $110K price. News

> Sanofi eyes superiority claim for Fluzone High-Dose after trial boost. More

CRO News

> U.K. outfit bets on early-phase outsourcing. News

> CRO Psi jumps into India. More

> Vince & Associates eyes gastro trials with expansion. Article

> Study: CROs dishing out bonuses to halt high turnover. Story

> Icon dives into adaptive trial monitoring. News

Biotech IT News

> Capgemini taps Amazon cloud for Big Data analytics. Story

> Harvard-MIT collaboration adds Lego-like genome analysis tool. Article

> Google bolsters security of cloud data storage service. More

> FDA pilot project ups benefits of IT supply chain investments. News

> EMA to start accepting digital signatures next month. Story

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.